You are here Home » Activities » Alumni Breakfasts » May 11, 2016: ”Pharma, Science, and Innovation: What Does the Future Hold for the Health Care Industry and for Patients?”
May 11, 2016: ”Pharma, Science, and Innovation: What Does the Future Hold for the Health Care Industry and for Patients?”
Jerry Avorn, The First Amendment and Pharmaceutical Promotion
Tufts Center for the Study of Drug Development, Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published , Press Release, March 10, 2016 PhRMA (Pharmaceutical Research and Manufacturers of America), Policy Solutions: Delivering Innovative Treatments to Patients PhRMA (Pharmaceutical Research and Manufacturers of America), Prescription Medicines: Costs in Context Jonathan J. Darrow, Jerry Avorn, & Aaron S. Kesselheim, New FDA Breakthrough-Drug Category – Implications for Patients Aaron S. Kesselheim, et al., Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study , Aaron S. Kesselheim, et al., The Roles of Academic, Rare Diseases, and Repurposing in the Development of the Most Transformative Drugs , Jerry Avorn & Aaron S. Kesselheim, Perspective, The 21st Century Cures Act – Will It Take Us Back in Time? , Aaron S. Kesselheim, et al., Characteristics of Clinical Trials to Support Approval of Orphan vs. Nonorphan Drugs for Cancer ,
